A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency

Archives of Internal Medicine

Volumn 160, Issue 2, 2000, Pages 181-188

  Dolovich, Lisa R ^a,b,c,d   Ginsberg, Jeffrey S ^d   Douketis, James D ^b,d   Holbrook, Anne M ^a,b,d   Cheah, Gillian ^b  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0034707685     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.2.181     Document Type: Article

References (62)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151: 933-938.
2. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 1995;155:1031-1037.
3. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1995;108(4 suppl):335S-351S.
4. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemost. 1985;54:813-817.
5. Hull RD, Pineo GF. Treatment of venous thromboembolism with low molecular weight heparins. Hematol Oncol Clin North Am. 1992;6:1095-1103.
6. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous untractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tasman Study. N Engl J Med. 1996;334:682-687
7. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
8. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996;100:269-277.
9. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecutar-weight heparins: a meta-analysis. Arch Intern Med. 1995; 155:601-607.
10. McMaster University Health Information Research Unit. Cochrane collaboration handbook. Available at: http://hiru.mcmaster.ca/cochrane/handbok/ cchb_05e.htm. Accessed October 1996.
11. Lensing AWA, Buller HR, Prandoni P, et al. Contrast venography: the gold standard for the diagnosis of DVT: improvement in observer agreement. Thromb Haemost. 1992;67:8-12.
12. White RH, McGahan JP, Daschbach MM, Harting RP. Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med. 1989;111:297-304.
13. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2759.
14. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med. 1992;116: 279-284.
15. Bettman MA, Robbins A, Braun SD, Wetzner S, Dunnick NR, Finkelstein J. Contrast venography of the leg: diagnostic efficacy, tolerance, and complication rates with ionic and nonionic contrast media. Radiology. 1987;165:113-116.
16. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute recurrent deep vein thrombosis: a diagnostic challenge. Circulation. 1983;67:901-906.
17. Prandoni P, Cogo A, Bernardi E, et al. A simple ultrasound approach for detection of recurrent proximal vein thrombosis. Circulation. 1993;88:1730-1735.
18. Huisman MV, Buller HR, ten Cate JW. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch Intern Med. 1988;148: 681-683.
19. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996;156:661-666.
20. Oxman AD, Cook DJ, Guyatt GH, for the Evidence-Based Medicine Working Group. Users' guide to the medical literature, VI: how to use an overview. JAMA. 1994; 272:1367-1371.
21. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons Inc; 1973:43-47.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
23. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993; 2:121-145.
24. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost. 1990; 64:506-510.
25. Prandoni P, Vigo M, Cattelan AM, Ruol A. Treatment of deep vein thrombosis by fixed doses of a low-molecular weight heparin (CY216). Haemostasis. 1990;20 (suppl 1):220-223.
26. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: a collaborative European multicentre study. Thromb Haemost. 1991;65: 251-256.
27. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
28. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.
29. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993;153: 1541-1546.
30. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994; 72:186-190.
31. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76:195-199.
32. Luomanmaki K, Grankvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med. 1996; 240:85-92.
33. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. N Engl J Med. 1997;337:657-662.
34. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
35. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost. 1992;68:14-18.
36. Zanghi M, Morici V, Costanzo M, Astuto L, Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. J Int Med Res. 1988;16:474-484.
37. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis. 1986:16(suppl 2):30-37.
38. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107-112.
39. Faivre R, Neuhart E, Kieffer Y, Toulemonde F, Bassand JP, Maurat JP. A new treatment of deep venous thrombosis: low molecular weight heparin fractions [in French]. Presse Med. 1988;17:197-200.
40. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis Clin Trials Meta-Analysis. 1993;28:215-225.
41. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11.
42. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. Circulation. 1989;80:935-940.
43. Lockner D, Bratt G, Tornebohm E, Aberg W, Granquist S. Intravenous and subcutaneous administration of Fragmin in deep vein thrombosis. Haemostasis. 1986; 16:25-29.
44. Bratt G, Aberg W, Tornebohm E, Granquist S, Lockner D. Subcutaneous KABI 2165 in the treatment of deep vein thrombosis of the leg [abstract]. Thromb Res. 1987;7(suppl):24.
45. Bratt GA, Tornebohm E, Johanson M, Aberg W, Granqvist S, Lockner D. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis. Acta Chir Scand Suppl. 1988;543:96-100.
46. Prandoni P. Fixed dose LMW heparin (CY216) as compared with adjusted dose intravenous heparin in the initial treatment of symptomatic proximal venous thrombosis [abstract]. Thromb Haemost. 1991;65(suppl):872.
47. Hull RD, Raskob GE, Pineo GF, et al. A randomized double-blind trial of low molecular weight heparin in the initial treatment of proximal vein thrombosis [abstract]. Thromb Haemost. 1991;65(suppl):872.
48. Janvier G, Winnock S, Dugrais G, et al. Treatment of deep vein thrombosis with a very low molecular weight heparin fragment (CY 222). Haemostasis. 1987;7: 49-58.
49. Force RW. Home treatment of deep venous thrombosis. J Fam Pract. 1996;42: 566-567.
50. de Valk HW, Banga JD, Wester JW, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial. Ann Intern Med. 1995;123:1-9.
51. Étude Multicentrique Française. Traitement des thromboses veineuses profondes constituées: étude comparative d'un fragment d'heparine de bas poids moléculaire (Fragmine) administrée par voie sous-cutanée et de l'heparine standard administrée par voie intraveineuse continue. Rev Med Interne. 1989;10: 375-381.
52. Notarbartolo A, Salanitri G, Davi G, Averna M, Barbagallo C, Catalano I. Low molecular weight heparin in the short-and long-term treatment of deep vein thrombosis in diabetic subjects. Med Prax. 1988;9:393-405.
53. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low-molecular-weight-heparin in acute venous thromboembolism. Haemostasis. 1990;20(suppl 1):205-219.
54. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. 1994;309:299-304.
55. Sciumbata T, Caretto P, Pirovano P, et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis. 1996;16:132-143.
56. Lersch C, Gericke D, Classen M. Efficacy of low-molecular weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers: an in vitro study and review of the literature. Urol Int. 1996;56:230-233.
57. Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost. 1998;79:897-901.
58. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300-304.
59. Hoppensteadt D, Walenga JM, Fareed J. Low molecular weight heparins: an objective overview. Drugs Aging. 1992;2:406-422.
60. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996;347:363-366.
61. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
62. Cook DJ, Guyatt GH, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest. 1995;108: 227S-230S.